Synairgen Research’s SNG001 inhaled drug, is being tested by the University of Southampton to treat asthma, chronic obstructive pulmonary disease and lower respiratory tract illnesses caused by coronavirus.
Rankings by 
Национальный рейтинг
70th
in United KingdomРегиональный рейтинг
339th
in Western EuropeГлобальный рейтинг
1523rd
worldwide